Pacira BioSciences, Inc. (PCRX) SEC Filings & Earnings Calls

Deal subject to customary closing conditions including regulatory approval and tender of majority of shares; risk of delay or failure.

“The transaction ... is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Pacira's common stock and expiration of the applicable regulatory waiting period.” · word for word

Dependence on EXPAREL for majority of revenue; GPO discount pressure.

“expansion of discount contracting programs related to group purchasing organizations (GPOs)” · word for word

Customer concentration

“Three largest wholesalers comprised 76% of total revenues for the three months ended June 30, 2026.”

Debt maturity risk

“Convertible senior notes due 2029 of $287.5 million principal; conversion conditions not met as of June 30, 2026.”

Tariff Exposure on Imported Products

“As a result of the Presidential Order, we expect tariffs to apply to the API used in EXPAREL, as well as EXPAREL and ZILRETTA product imported from the U.K.” · word for word

Generic Competition for EXPAREL

“In October 2025, we received two separate Paragraph IV Certifications from two Chinese generic drug manufacturers... each advising that they had submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking authorization to manufacture, use or sell a generic version of EXPAREL in the U.S.” · word for word

Contested Board Election Costs

“we expect to incur additional costs within general and administrative expenses in the second quarter of 2026 related to the solicitation of proxies in connection with a contested election of directors” · word for word

GAAP profitability declined despite revenue growth

“GAAP net income $2.9M vs $4.8M; adjusted EBITDA $40.2M vs $44.1M”

R&D and SG&A expenses increased, pressuring margins

“R&D $28.1M vs $25.3M; SG&A $93.9M vs $86.8M”

Activist pressure for sale process

“DOMA urged the Board to conduct a formal sale process of the Issuer to maximize the value of the Issuer's assets and realize value for the Issuer's shareholders.” · word for word

Activist pressure for sale process

“DOMA urged the Board to conduct a formal sale process of the Issuer to maximize the value of the Issuer's assets and realize value for the Issuer's shareholders.” · word for word

Generic competition to EXPAREL

“In July 2024, the FDA approved a generic competitor to EXPAREL and in August 2024, a U.S. District Court ruled that one of our EXPAREL patents was not valid.” · word for word

Significant contingent consideration liability

“The maximum remaining potential payments related to contingent consideration from the Flexion Acquisition is $372.3 million as of December 31, 2025.” · word for word

Need for additional capital

“We may need to raise additional capital to continue to fund our operations; continue our efforts to hire additional personnel and build a commercial infrastructure to commercialize EXPAREL, ZILRETTA and iovera°; qualify, outsource or build additional commercial-scale manufacturing of our products in accordance with CGMP; acquire, in-license and develop addit” · word for word

NOL carryforward limitation

“Our ability to use certain NOLs to offset taxable income in the future will be limited under Internal Revenue Code Section 382 because we experienced cumulative changes in ownership of more than 50% within a three-year period.” · word for word

Preliminary results subject to adjustment; ZILRETTA sales slightly declining; discounting from GPO partnerships may pressure margins.

“discounting associated with the launch of a new group purchasing organization (GPO) partnership” · word for word

Impairment of acquired in-process R&D of $25.9 million indicates potential pipeline setbacks.

“Included in operating expenses in the third quarter of 2025 was a $25.9 million impairment of acquired in-process research and development.” · word for word

Increased R&D and SG&A expenses may pressure margins if revenue growth slows.

“R&D expenses were $26.0 million... compared to $19.1 million... SG&A expenses were $91.8 million... compared to $74.3 million.” · word for word

Generic competition to EXPAREL

“During the three months ended September 30, 2024, the U.S. Food and Drug Administration, or FDA, approved a generic competitor to EXPAREL and a U.S. District Court ruled that one of the Company’s patents was not valid.” · word for word

IPR&D impairment risk

“During the three months ended September 30, 2025, the Company determined the fair value of the ZILRETTA acquired IPR&D for the treatment of shoulder OA pain may be at risk of impairment due to revised completion timelines for clinical trials and commercial availability which directly impacted revenue forecasts, among other factors.” · word for word

Customer concentration

“Total 77% for the three months ended September 30, 2025.”